Dabrafenib Mesylate(GSK-2118436B)

Base Information

• Chemical Name: Dabrafenib Mesylate(GSK-2118436B)
• CAS No.: 1195768-06-9
• Molecular Formula: C24H24F3N5O5S3
• Molecular Weight: 615.678
• Hs Code.: 2935909099
• Mol file: 1195768-06-9.mol

Synonyms:Dabrafenib Mesylate(GSK-2118436B);Dabrafenib Mesylate;GSK 2118436 Mesylate;GSK 2118436B;GSK2118436 Mesylate;GSK-2118436 Mesylate;Dabrafenib Mesylate (API);GSK 2118436 methanesulfonate salt

Chemical Property of Dabrafenib Mesylate(GSK-2118436B)

Chemical Property:

• PSA: 210.96000
• LogP: 7.03360
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility.: DMSO (Slightly, Heated), Methanol (Slightly)

Purity/Quality:

99.0%, High purity. ^*data from raw suppliers

DabrafenibMesylate ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Description: Dabrafenib Mesylate is a salt form of Dabrafenib. Dabrafenib is an inhibitor of certain mutated forms of BRAF kinase, several of which may be associated with stimulating tumour growth (e.g. the BRAF V600E mutation), and Dabrafenib is also an inhibitor of BRAF V600-mutation positive cancer cell growth, both in vitro and in vivo. Dabrafenib mesylate, sold by GlaxoSmithKline under the trade name Tafinlar, was approved by the U.S. FDA in May 2013 for the treatment of metastatic BRAF-mutant melanoma. Dabrafenib reversibly inhibits the BRAF(V600E) mutant kinase as a selective ATP-competitive inhibitor which results in tumor regression.

Technology Process of Dabrafenib Mesylate(GSK-2118436B)

There total 7 articles about Dabrafenib Mesylate(GSK-2118436B) which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 87.0%

methanesulfonic acid (75-75-2,98527-29-8) + dabrafenib (1195765-45-7) → N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide methanesulfonic acid (1195768-06-9)

Guidance literature:

In isopropyl alcohol; at 20 ℃; for 3h;

Reference yield:

3-(2,6-difluorobenzenesulfonamido)-2-fluorobenzoic acid methyl ester (1195768-19-4) → N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide methanesulfonic acid (1195768-06-9)

Guidance literature:

Multi-step reaction with 4 steps

1.1: lithium hexamethyldisilazane / tetrahydrofuran / 1 h / 0 - 3 °C

2.1: N-Bromosuccinimide / dichloromethane / 10 - 20 °C

2.2: 2.5 h / 10 - 75 °C

3.1: ammonium hydroxide / water / 20 - 103 °C / sealed tube

4.1: acetonitrile; water / 20 - 60 °C

With ammonium hydroxide; N-Bromosuccinimide; lithium hexamethyldisilazane; In tetrahydrofuran; dichloromethane; water; acetonitrile;

Reference yield:

2,6-difluorobenzene-1-sulfonyl chloride (60230-36-6) → N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide methanesulfonic acid (1195768-06-9)

Guidance literature:

Multi-step reaction with 5 steps

1.1: pyridine / dichloromethane / 15 - 25 °C

2.1: lithium hexamethyldisilazane / tetrahydrofuran / 1 h / 0 - 3 °C

3.1: N-Bromosuccinimide / dichloromethane / 10 - 20 °C

3.2: 2.5 h / 10 - 75 °C

4.1: ammonium hydroxide / water / 20 - 103 °C / sealed tube

5.1: acetonitrile; water / 20 - 60 °C

With pyridine; ammonium hydroxide; N-Bromosuccinimide; lithium hexamethyldisilazane; In tetrahydrofuran; dichloromethane; water; acetonitrile;

upstream raw materials:

methanesulfonic acid

dabrafenib

2,6-difluorobenzene-1-sulfonyl chloride

N-(3-(2-(2-chloropyrimidin-4-yl)acetyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide

Refernces

• 1、 -. "PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE B-RAF INHIBITOR DABRAFENIB; THE USE OF SUCH COMBINATION IN THE TREATMENT OR PREVENTION OF CANCER". Page/Page column 32-33. . Retrieved 2017/03/21.
• 2、 -. "COMBINATIONS OF TRAMETINIB, PANITUMUMAB AND DABRAFENIB FOR THE TREATMENT OF CANCER". Page/Page column 25; 26. . Retrieved 2015/06/25.